Sökning: onr:"swepub:oai:DiVA.org:umu-193007" >
Progression pattern...
Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome : a cohort study in 42 patients
-
- Tahiru, Widad (författare)
- Umeå universitet,Onkologi
-
- Izarra Santamaria, Antonio (författare)
- Umeå universitet,Onkologi
-
- Hultdin, Johan (författare)
- Umeå universitet,Klinisk kemi
-
visa fler...
-
- Wu, Wendy Yi-Ying (författare)
- Umeå universitet,Onkologi
-
- Späth, Florentin, 1980- (författare)
- Umeå universitet,Onkologi
-
visa färre...
-
(creator_code:org_t)
- 2022-02-23
- 2022
- Engelska.
-
Ingår i: Experimental Hematology & Oncology. - : BioMed Central (BMC). - 2162-3619. ; 11:1
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
https://ehoonline.bi...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Follow-up of low-risk monoclonal gammopathy of undetermined significance (MGUS) is debated as multiple myeloma (MM) progression risk is low. Worse MM outcome was reported for patients followed for low-risk MGUS, possibly due to less optimal follow-up. However, it is unknown whether progressing low-risk MGUS is associated with aggressive tumor behavior. Understanding these patterns is crucial for MGUS management. Here, we investigated whether progression from low-risk MGUS is associated with worse MM outcome in patients who had no MGUS follow-up before myeloma diagnosis. We retrospectively determined the MGUS status in repeated pre-diagnostic blood samples prospectively collected from 42 myeloma patients in median 11.6 years (first sample) and 3.3 years (repeated sample) before myeloma diagnosis. At first pre-diagnostic blood draw, 12 had low-risk (defined by an immunoglobulin [Ig] G monoclonal [M] spike < 15 g/L and a normal free light-chain ratio) and 30 had MGUS of other risk. MM bone disease was more common in patients with low-risk MGUS at first blood draw (67% vs. 30%, P = 0.041). Median survival since myeloma diagnosis was worse in low-risk than other MGUS at first blood draw (2.3 vs. 7.5 years, P = 0.004). Modest progression was observed between first and repeated blood draw for the majority of low-risk MGUS as 67% remained as low- or low-intermediate-risk MGUS at repeated blood draw. Our study, albeit limited by its small size, indicates that progression from low-risk MGUS is associated with worse MM outcome regardless of MGUS follow-up. Although further investigation is needed, progressing low-risk MGUS could belong to a group of aggressive tumors with progression that is difficult to predict.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Aggressive myeloma
- Low-risk MGUS
- MGUS
- MGUS follow-up
- MGUS progression
- Multiple myeloma
- Myeloma outcome
- NSHDS
- Prospective blood samples
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas